Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

(2018) Ivana Sestak et al.   JAMA Oncology

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

(2018) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Eleftherios P Mamounas et al.   LANCET ONCOLOGY

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

(2017) M.J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

NCCN Guidelines Insights: Breast Cancer, Version 1.2017

(2017) William J. Gradishar et al.   Journal of the National Comprehensive Cancer Network

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

(2017) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2016) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

(2015) Meredith M. Regan et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

(2015) Prudence A. Francis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

(2014) Olivia Pagani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

(2013) Dennis C. Sgroi et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

(2013) Dennis C Sgroi et al.   LANCET ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial

(2011) John M.S. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types

(2011) Sherene Loi et al.   LANCET ONCOLOGY

Adaptive increase in sample size when interim results are promising: A practical guide with examples

(2010) Cyrus R. Mehta et al.   STATISTICS IN MEDICINE

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

(2008) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY